Close Menu

NEW YORK – The US Food and Drug Administration announced on Wednesday it will no longer review SARS-CoV-2 Emergency Use Authorization submissions for lab-developed tests.

In the latest of its weekly virtual town hall sessions, the agency asserted that the change is consistent with the recent statement by the US Department of Health and Human Services and will also help FDA prioritize the review process during the pandemic.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.